Genenta Science (NASDAQ:GNTA)‘s stock had its “buy” rating restated by equities research analysts at Roth Capital in a research report issued to clients and investors on Wednesday, Zacks.com reports.
Separately, Maxim Group began coverage on Genenta Science in a research report on Thursday. They set a “buy” rating and a $21.00 target price for the company.
Shares of GNTA stock opened at $10.21 on Wednesday. Genenta Science has a 12 month low of $9.10 and a 12 month high of $13.13.
Genenta Science S.p.A. is a clinical-stage biotechnology company pioneering the development of hematopoietic stem progenitor cell immuno-gene therapy for solid tumors, including the lead product candidate, Temferon(TM). Genenta Science S.p.A. is based in MILAN, Italy.
Featured Article: What is the return on assets formula?
Receive News & Ratings for Genenta Science Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genenta Science and related companies with MarketBeat.com's FREE daily email newsletter.